CSLCSL Limited

CSL rose sharply alongside a broad and unusually large rally in the Australian healthcare sector, suggesting a powerful sector-wide rotation or rerating event drove the move rather than any company-specific news.

CSL's share price surged after the company released a market-sensitive update on enhanced plasma manufacturing, which also lifted the broader ASX health sector strongly on the same day.

CSL shares surged on a defensive rotation into healthcare stocks as the materials sector slumped and the broader ASX 200 fell.

CSL shares surged on June 5, 2026, as a broad healthcare sector turnaround was reported after a challenging May.

CSL cut fiscal year 2026 guidance and flagged approximately $5 billion in additional impairments, leading to a massive share price decline.

CSL shares fell sharply, catching a broader sell-off in the ASX healthcare sector triggered by Cochlear's shock news.

CSL shares fell sharply after its half-year earnings showed a drop in profit, disappointing the market.

CSL shares fell sharply after the company reported disappointing half-year earnings, with profit drops and margin compression shaking investor confidence.

CSL shares rebounded 5.15% on October 29 after a sharp 17% crash on October 28, driven by a slash to its FY26-28 growth outlook and a second remuneration strike.

CSL slashed its FY26-28 growth outlook, triggering a massive sell-off to a six-year low.

CSL shares plunged 16.89% following its FY25 results, which disappointed the market and included plans to demerge its Seqirus business.